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Abstract
The aim of this study is to ascertain the burden of pre-clinical atheroscleroticchanges in the brains of young adult males with 
HIV and explore the impact ofanti-retroviral therapy (ART). The study design is case-control, cross-sectional. Histological 
sections from HIV-positivepost-mortem brain samples, with no associated opportunistic infection, from theMRC Edinburgh 
brain bank were evaluated. These were age and sex matched with HIV-negativecontrols. Immunohistochemical stains were 
performed to evaluate characteristicsof atherosclerosis. The pathological changes were graded blinded to the HIVstatus and a 
second histopathologist reassessed 15%. Univariable models wereused for statistical analyses; p≤0.05 was considered signifi-
cant.Nineteen HIV-positivepost-mortem cases fulfilled our inclusion criteria. Nineteen HIV-negativecontrols were selected. 
We assessed mostly small-to medium-sized vessels. For inflammation (CD45), 7 (36%) of the HIV+ had moderate/severe 
changes compared withnone for the HIV− group (p<0.001). Moderate/severeincrease in smooth muscle remodeling (SMA) 
was found in 8 (42%) HIV+ and 0 HIV− brains (p<0.001).Moderate/severe lipoprotein deposition (LOX-1) was found in 3 
(15%) and 0 HIV−brains (p<0.001). ART was associated with less inflammation [5 (63%) noART versus 2 (18%) on ART 
(p=0.028)] but was not associatedwith reduced lipid deposition or smooth muscle damage. InHIV infection, there are pre-
clinical small- to medium-sized vesselatherosclerotic changes and ART may have limited impact on these changes. Thiscould 
have implications on the increasing burden of cerebrovascular disease inHIV populations and warrants further investigation.
Keywords HIV · Post-mortem · Atherosclerosis · Cerebrovascular disease · Art
Introduction
In the era of anti-retroviral therapy (ART), the phenotype of 
individuals infected with HIV has changed. The combined 
effect of long-term ART, chronic HIV infection with virological 
suppression, and advancing age is altering the disease pattern 
(Gutierrez et al. 2016; Sico et al. 2015; Sacktor et al. 2016; Deeks 
et al. 2013). For example, stroke and neurocognitive impairment 
are increasingly more prevalent in treated HIV individuals 
(Sacktor et al. 2016; Gutierrez et al 2015). The mechanism is 
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unclear and likely multifactorial (Sico et al. 2015). However, 
accelerated atherosclerotic disease is thought to underlie the 
increasing burden of cerebrovascular disease, especially in 
high-income countries (Benjamin et al. 2012). The effects of a 
dysregulated immune system, endothelial dysfunction, deranged 
metabolic disturbance and ART toxicity have all been postulated 
to accelerate atherosclerosis (Deeks et al. 2013; Gutierrez et al. 
2015; Benjamin et al. 2012). The association with low nadir 
CD4 count and cerebrovascular disease also suggests that 
early biological activities may predispose individuals to future 
cerebrovascular events (Gutierrez et al. 2016; McArthur and 
Smith 2013). Studies thus far have relied on soluble biomarkers 
in the blood and correlated this to surrogate markers of 
cardiovascular disease such as coronary arterial remodelling 
(Miller et al. 2015) and carotid intimal media thickness (Hsue 
et al. 2012). Only a handful of studies have looked at post-
mortem brain tissue to explore the mechanism of cerebrovascular 
disease in HIV infection; two have specifically focused on large 
vessel remodelling and inflammation in less advanced diseases 
(Gutierrez et al. 2016, 2015) and one on crude small vessel 
neuropathological changes in AIDS patients (Connor et al. 2000). 
To date, no study has considered the specific components that 
define atherosclerosis (inflammation, lipid deposition and smooth 
muscle remodelling) in HIV populations and the impact of ART 
on small- to medium-sized vessels. To bridge this gap, we looked 
for pre-clinical atherosclerotic changes in HIV-infected post-
mortem brain in the early phase of HIV infection and the impact 
ART has on these changes.
Methods
The study was carried out at the Centre for Clinical Brain 
Sciences, University of Edinburgh, and samples were obtained 
from the Medical Research Council (MRC) Edinburgh brain 
bank, UK. These included patients who died between 1989 
and 2003. Formalin-fixed paraffin-embedded post-mortem 
brain samples from HIV-positive patients were selected. 
Those with opportunistic CNS infections or neoplasia were 
excluded. Age- and sex-matched HIV-negative controls 
were also selected applying the same exclusion criteria. 
The causes of death in both cases and controls are listed in 
Table 1. Ethical approval was sought and approved by the East 
of Scotland Research Ethics Service (16/ES/0084). For each 
sample, sections were taken from the frontal convexity and 
basal ganglia. Haematoxylin and Eosin (H&E) staining was 
performed to assess the general overview of vascular changes.
Histological assessment
All cases were reviewed, and the assessor was blinded to 
their HIV status. H&E sections were initially assessed 
for classical characteristics of small vessel disease 
(arteriolosclerosis and lipohyalinosis).
Immunohistochemistry
Immunohistochemical stains were performed to evaluate 
atherosclerotic changes. We looked specifically for smooth 
muscle damage, inflammation, and lipid deposition. CD31 
(1:100 Dako) was used to detect vascular endothelia cells, 
HIV-1 p24 (1:50 Dako) for detection of HIV infected 
cells, leukocyte common antigen (CD45) (1:100 Dako) 
for detection of inflammation (lymphocytes), lectin-like 
oxidized low-density lipoprotein receptor-1 (LOX-1) 
(1:50 Abcam) for detection of lipid deposition (lipid laden 
macrophages), and smooth muscle actin (SMA) (1:500 
Dako) for detection of vascular smooth muscle proliferation/
disruption/damage. Positive control tissues included tonsil 
(CD31 and CD45), brain for HIV-1 p24, large vessel 
Table 1  Demographic and 
clinical characteristics of 
HIV-positive and negative 
populations studied
a Other; common causes in this category included drowning and trauma
HIV group (n = 19) Control group (n = 19)
Median age, year (IQR) 30 (28–34) 30 (25–37)
Duration of HIV infection median years 
(IQR)
6(3.5–8.75) -
ART (%) 11 (58%) -
AZT alone 7 (63%) -
AZT combination 3 (27%) -
Stavudine 1(9%) -
Median CD4 count cells/mm3 45(18–60) -
Cause of death
Pneumonia 11 (57%) -
Drug overdose/alcohol 3 (16%) 5 (26%)
Heart disease 1 (5%) 7 (37%)
Othersa 4 (21%) 7 (37%)
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atherosclerosis for LOX-1, and large bowel for SMA. The 
primary antibody was withheld in negative control.
Grading of vascular changes and size
Atherosclerotic changes were graded from normal (no feature 
of atherosclerosis) through mild (+), moderate (2+) and severe 
(3+) (Fig. 1) using modification of methods that have been 
described previously (Fujishiro et al. 2011). Inflammation was 
graded by the extent of perivascular cuffing of lymphocytes; 
lipid deposition was graded according to the increasing 
number of lipid-laden macrophages. Smooth muscle 
damage was evaluated based on severity of degenerative 
changes and mal-alignment (disruption) of smooth muscle 
fibres. The arterial vessels were grouped according to their 
size: small vessels (diameter  =  100–300  µm), small- to 
medium-sized vessels (diameter > 300–1000 µm), medium-
sized vessel (> 1000–10,000 µm) and large-sized vessels 
(diameter > 10,000 µm).
Analysis
Grading of each slide was performed 3 times with an average 
taken. A second histopathologist assessed reliability of the 
grading technique by random selection of 15% of the total 
samples. Weighted kappa statistics were used to determine 
the level of agreement. Comparisons were made with a post-
mortem specimen of the coronary artery of an elderly man 
with severe atherosclerosis, who died of a haemorrhagic stroke; 
this was done to confirm that the characteristics of established 
Fig. 1  Evidence of pre-clinical atherosclerosis among our HIV popu-
lation: inflammation—CD45 staining showing perivascular cuffing of 
lymphocytes a normal–less than 4 lymphocytes, b mild–linear lym-
phocytic infiltrates, c moderate–partial layering of lymphocytic infil-
trates, d severe–circumferential layering of infiltrates with oblitera-
tion of vascular lumen. Lipid deposition—LOX-1 staining showing 
lipid-laden macrophages (lipophages) in the vessel wall e normal–
no lipophage, f mild > 6 lipophages, g moderate–partial layering of 
lipophages, h severe–circumferential layering of lipophages smooth 
muscle damage—SMA staining showing disruption of vascular 
smooth muscle i normal–no disruption of muscle fibres, j mild–focal 
separation of muscle fibres, k moderate–prominent separation of 
muscle fibres, l severe–disruption of vascular wall with alteration in 
vessel outline. Magnification × 20
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atherosclerosis were consistent with those seen in the HIV 
population.
Results were presented as proportions (classified as nor-
mal/mild/moderate/severe). Quantitative variables were 
expressed as medians with interquartile ranges. Fisher exact/
Chi-squared test was used to compare categorical data and 
Mann-Whitney U for continuous variable. A p value of 
≤ 0.05 was taken as significant.
Results
Description of the cohort
From 168 HIV-positive post-mortems, we identified 19 
men without opportunistic infections. The median age was 
30 (IQR = 28–34), and the median CD4+ count was 45 
(IQR = 18–60). The characteristics of the cohort are reported 
in Table 1. The validation of grading process showed 97% 
agreement between two independent observers. The overall 
weighted kappa (K) was 0.80 (Std. Err ± 0.16, p < 0.0001).
CD31 immunolabelling detected endothelial cells in both 
case and control groups. HIV infection was confirmed by 
evidence of positive HIV-1 P24 antibody in 18/19 (95%) 
HIV-positive cases. The only case negative for HIV-1 P24 
had diagnosis of HIV at autopsy with very low viral count, 
indicating recent seroconversion.
Evidence of pre‑clinical atherosclerosis
This study focused predominantly on small-medium-sized 
vessels of the basal ganglia and frontal convexity, both of 
which demonstrated similar features. There was no evi-
dence of classical small vessel disease pathology, and no 
lacunar infarcts were seen. Similar features (Fig. 1) show the 
spectrum of pre-clinical atherosclerosis found in our HIV 
population.
When looking specifically at inflammation, there were 9 
(47%) mild, 5 (26%) moderate and 2 (10.5%) severe cases 
of perivascular cuffing of lymphocytes in the HIV-positive 
group whilst in the HIV-negative group, 2 (10.5%) were 
mild, 17 (89.5%) were normal, and there were no moderate 
or severe changes (p value < 0.001).
For lipid deposition, 15 (79%) cases were mild, 1 (5%) 
moderate and 2 (10.5%) severe in the HIV-positive group. 
There was no evidence of lipid deposition in the control 
group (p value < 0.001).
For vascular smooth muscle damage, there were 9 (47%) 
mild, 6 (32%) moderate and 2 (10.5%) severe cases, whilst 
for the control group, 10 (53%) were mild and 9 (47%) were 
normal; there were no moderate or severe changes in the 
control group (p value < 0.001).
The effect of anti‑retroviral therapy (ART)
Being on ART was associated with less inflammation [5 
(63%) no ART versus 2 (18%) on ART (p = 0.028)]. There 
was no difference seen between ART and non-ART cases 
regarding lipid deposition and vascular smooth muscle 
damage (Supplement Table 1).
Comparison with classical changes 
of atherosclerosis
Changes identified in the control case with classical 
atherosclerosis were consistent with those seen in the HIV-
positive group (Supplement Figure 1).
Discussion
Our study, of adult males with advanced HIV infection, 
showed significant evidence of perivascular inflammation, 
lipid deposition and vascular smooth muscle damage, in 
small-to-medium-sized vessels when compared with 
controls of similar age and sex. Treatment of HIV infection 
was associated with a lower degree of perivascular 
inflammation but had no significant effect on lipid 
deposition and vascular smooth muscle damage.
Previous studies have shown that in HIV infection, 
intracranial arterial remodelling including intimal 
thickening and media thinning is common in large arteries 
when compared with an age- and sex-matched HIV-
negative cohort and occurs in the context of inflammation 
(Gutierrez et al. 2016; Gutierrez et al. 2015). We expand 
the spectrum by demonstrating pre-clinical atherosclerotic 
changes in small-to-medium-sized arterial vessels, and in 
addition to inflammation, we observed lipid deposition and 
smooth muscle damage. Histologically, these changes were 
not typical of either arteriolosclerosis or lipohyalinosis 
but suggest accelerated small vessel atherosclerosis. We 
did not corroborate the findings with large arterial vessel 
disease, largely due to the choice of sections used for 
our analysis. Despite this, pre-clinical atherosclerotic 
changes are common in younger individuals at a relatively 
early stage of their HIV infection and could predispose 
HIV-infected individuals to stroke and neurocognitive 
morbidity. Notably, a radiological review of 60+ HIV-
positive stroke patients had a significantly higher number 
of basal ganglia stroke subtype when compared with 
an HIV-negative group. Because basal ganglia stroke 
is largely caused by disease of small-to-medium-sized 
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arteries, this observation is consistent with our findings 
(Benjamin et al. 2017).
Whilst perivascular inflammation may be reduced by 
ART use, it may not arrest the remodelling process (i.e. 
smooth muscle damage and lipid deposition), as suggested 
from our results. Although our numbers are too small to 
be definitive, our observation is consistent with the wider 
epidemiological view that the prevalence of stroke and 
cognitive impairment remains higher than the respective 
HIV-negative population, despite the use of ART (Sacktor 
et al. 2016; Ovbiagele and Nath 2011). Persistent immune 
activation, metabolic dysregulation due to HIV or ART itself 
and ART toxicity are all potential mechanisms that have 
been postulated (Deeks et al. 2013; Gutierrez et al. 2015; 
Benjamin et al. 2012). The latter could be relevant given 
the use of drugs like Stavudine during this era.  However, 
Stavudine use was uncommon in our cohort.
What remains unclear is whether events at the early phase of 
HIV infection predispose individuals to future cerebrovascular 
disease. The historic association with a low nadir CD4+ count, 
among those with stable HIV infection, and cerebrovascular risk, 
is of course, compelling in this debate (Gutierrez et al. 2015; 
McArthur and Smith 2013). However, the recent introduction 
of ART in asymptomatic patients (Lundgren et al. 2015) may 
address this issue. Importantly, as our study suggests, ART may 
have very little impact on vascular atherosclerotic changes, and 
therefore, a more definitive evaluation with a larger autopsy 
cohort would be a critical step forward in clarifying this issue.
This study does have some limitations. Although 
the sample size was small, this pilot work highlights 
observations at a biological level that are consistent 
with epidemiological observations. We were unable to 
determine the prevalence of vascular risk factors such as 
smoking, hypertension and diabetes in our population, and 
it is plausible that these unmeasured factors could have 
confounded our results. However, in an independent study 
of a similar population, these factors were uncommon, so 
unlikely to have affected our findings (Connor et al. 2000). 
These findings are only relevant to men. The availability of 
post-mortem sections of the brain among individuals with 
HIV infection is limited. We therefore relied on a historical 
cohort of individuals who died between 1989 and 2003 when 
ART was limited to zidovudine and/or a nucleoside reverse 
transcriptase inhibitor (NRTIs). Although there is some 
overlap with current combination therapies, generalisation 
of our findings will have to be taken in the context of this 
limitation. However, a recent study exploring the early 
initiation of ART versus delayed ART, in asymptomatic HIV 
infection, showed no benefit in preventing cardiovascular 
disease, among the early initiators of ART; this is consistent 
with our findings (Lundgren et al. 2015).
In conclusion, preclinical atherosclerotic changes of 
small-to-medium-sized intracranial arteries are seen 
within the first 6 years of HIV infection. ART may reduce 
inflammation but does not appear to impact on arterial 
remodelling. Further research should focus on clarifying 
the role of ART on intracranial arterial remodelling.
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